« Previous |
1 - 10 of 21
|
Next »
Number of results to display per page
Search Results
2. Český lid | 2009 Volume:96 | Number:2
- Type:
- model:periodicalitem and TEXT
- Language:
- Czech, Slovak, and English
- Description:
- 2
- Rights:
- http://creativecommons.org/publicdomain/mark/1.0/ and policy:public
3. Český lid | 2009 Volume:96 | Number:3
- Type:
- model:periodicalitem and TEXT
- Language:
- Czech, Slovak, and English
- Description:
- 3
- Rights:
- http://creativecommons.org/publicdomain/mark/1.0/ and policy:public
4. Český lid | 2009 Volume:96 | Number:4
- Type:
- model:periodicalitem and TEXT
- Language:
- Czech, Slovak, and English
- Description:
- 4
- Rights:
- http://creativecommons.org/publicdomain/mark/1.0/ and policy:public
5. Dyslipidémie u seniorov: liečiť, či neliečiť?
- Creator:
- Pytliak, Marek, Vargová, Viola, Mechírová, Viola, and Benhatchi, Karim
- Type:
- model:article, article, Text, and TEXT
- Subject:
- lidé, staří, dyslipidemie--diagnóza--terapie, stupeň závažnosti nemoci, ateroskleróza--diagnóza--terapie, statiny--aplikace a dávkování, kyselina klofibrová--analogy a deriváty--aplikace a dávkování, prospektivní studie, and analýza nákladů a výnosů
- Language:
- Czech, Slovak, and English
- Description:
- Liečiť alebo neliečiť dyslipidémie u seniorov? To je otázka. Je pravdepodobné, že v prítomnosti pokročilej aterosklerózy a cievnych kalcifikácií u starých pacientov bude hypolipemická liečba menej úspešná v primárnej aj sekundárnej prevencii kardiovaskulárnych ochorení. Na druhej strane, v tejto skupine pacientov klesá aj bezpečnosť hypolipemickej liečby. Tieto faktory prispievajú k modifikácii pomeru risk/ benefit farmaceutickej liečby dyslipidémií. Napriek výsledkom niektorých štúdií, ktoré spochybnili asociáciu medzi koncentráciami cholesterolu a kardiovaskulárnym rizikom v starobe, cholesterol zostáva významným, ovplyvniteľným rizikovým faktorom aj u pacientov nad 65 rokov, najmä po zohľadnení ďalších komorbidít. Narastajúce dáta, primárne aj sekundárne, v preventívne orientovaných štúdiách potvrdzujú benefit hypolipemickej liečby u vysokorizikových, starých pacientov. Všetci indikovaní pacienti v tejto vekovej skupine by mali byť liečení podľa najnovších odporúčaní medicíny založenej na dôkazoch., To treat or not to treat dyslipidemias in the eldery? That is the question. It is likely that lipid lowering therapy will be less successful in the primary as well as the secondary prevention of cardiovascular events in the presence of advanced atherosclerosis and artery calcification in older patients. On the other hand, safety of lipid lowering therapy in this patient group becomes more problematic. These factors contribute to the modification of the risk/ benefit ratio of pharmaceutical lipid lowering therapy in this population. Even though the results of several studies challenged the association between cholesterol concentrations and cardiovascular risks in older patients, cholesterol remains an important modifiable risk factor in patients over 65 years of age, especially after adjusting for the presence of co/ morbidities. Growing evidence from studies focusing on primary as well as the secondary prevention confirms the benefit of treating high-risk older patients with lipid lowering drug therapy. Therefore, all patients in this age group for whom such treatment is indicated should be treated in accordance with the most current recommendations of the evidence-based medicine., Marek Pytliak, Viola Vargová, Viola Mechírová, Karim Benhatchi, and Lit.: 19
- Rights:
- http://creativecommons.org/publicdomain/mark/1.0/ and policy:public
6. Možnosti predikcie rezistencie k neoadjuvantnej konkomitantnej chemorádioterapii u pacientov s karcinómom konečníka
- Creator:
- Garajová, Ingrid, Svoboda, M., Kocáková, Ilona, Fabian, Pavel, Kocák, Ivo, Vyzula, Rostislav, and Slabý, Ondřej
- Type:
- model:article, article, Text, and TEXT
- Subject:
- adenokarcinom--farmakoterapie--chirurgie--radioterapie, antimetabolity antitumorózní--terapeutické užití, chemoterapie adjuvantní, deoxycytidin--analogy a deriváty--terapeutické užití, fluorouracil--analogy a deriváty--terapeutické užití, lidé, neoadjuvantní terapie, prognóza, radioterapie adjuvantní, nádory rekta--farmakoterapie--chirurgie--radioterapie, výsledek terapie, and nádorové biomarkery--analýza
- Language:
- Czech, Slovak, and English
- Description:
- Neoadjuvant concomitant chemoradiotherapy has become a standard treatment of locally advanced rectal adenocarcinomas (LARA). It leads to shrinkage of the tumor mass and subsequently to an increase in complete resections (R0 resections), increasing a feasibility of sphincter-sparing intervention avoiding colostomy. It is based on concurrent application of fluoropyrimidines (5-fluorouracil, capecitabine) and radiotherapy (45 - 50,4 Gy). It shows less acute toxicity and improves local control rate in comparison to adjuvant treatment. Unfortunately, neoadjuvant chemoradiotherapy is not beneficial for all patients. The treatment response ranges from a complete pathological remission (pCR, ypT0ypN0) to a resistance. It is reported that cca 15 percent of patients with advanced rectal cancer show pCR which is indicative of improved long-term prognosis. DESIGN: The following is a review of the significance of neoadjuvant concomitant chemoradiotherapy in the treatment algorithm of patients with LARA and summary of potentional clinical-pathological and molecular markers of response prediction to neoadjuvant therapy. The most important clinical studies concern serum tumor markers levels, clinical lymph node classification. The components of the carcinogenic pathways are explored, including oncogenes, tumor supressor genes, microsatellite instability (MSI) and potentional markers involved in apoptosis, angiogionesis, proliferation as well as metastasis and invasion, are reviewed. Finally, the role of specific enzymes associated with the metabolism of fluoropyrimidines are examined. CONCLUSIONS: No one marker has been consistently identified as clinically applicable. Studies designed to determine the potentional markers are hampered by various techniques as well as tumor heterogenity and recent scientific approach--studying individual molecular markers. Gene expression profiling analysis of multiple genes from the same tumor is becoming reality. We suppose that this assessment will lead in future in finding combination of markers for predicting prognosis and response to therapy in rectal cancer., Garajová Ingrid, Svoboda M., Slabý O., Kocáková L., Fabian P., Kocák I., Vyzula R., and Lit.: 71
- Rights:
- http://creativecommons.org/publicdomain/mark/1.0/ and policy:public
7. Organon F: filozofický časopis
- Type:
- model:periodicalitem and TEXT
- Language:
- Slovak and English
- Description:
- 1
- Rights:
- http://creativecommons.org/publicdomain/mark/1.0/ and policy:public
8. Organon F: filozofický časopis
- Type:
- model:periodicalitem and TEXT
- Language:
- Slovak and English
- Description:
- 4
- Rights:
- http://creativecommons.org/publicdomain/mark/1.0/ and policy:public
9. Organon F: filozofický časopis
- Type:
- model:periodicalitem and TEXT
- Language:
- Slovak and English
- Description:
- 2
- Rights:
- http://creativecommons.org/publicdomain/mark/1.0/ and policy:public
10. Organon F: filozofický časopis
- Type:
- model:periodicalitem and TEXT
- Language:
- Slovak and English
- Description:
- 3
- Rights:
- http://creativecommons.org/publicdomain/mark/1.0/ and policy:public
- « Previous
- Next »
- 1
- 2
- 3